Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Wilson

Showing results (281-290 of 328) with videos related to

Pageof 33
Sort By:
Biorxiv : the Preprint Server for Biology|June 9, 2023
Chemoenzymatic syntheses of fluorine-18-labeled disaccharides from [ Alexandre M Sorlin, Marina López-Álvarez, Sarah J Rabbitt, et al.
Nucleic Acids Research|January 2, 2015
DNA polymerase β deficiency leads to neurodegeneration and exacerbates Alzheimer disease phenotypesPeter Sykora, Magdalena Misiak, Yue Wang, et al.
Bioorganic & Medicinal Chemistry|July 30, 2010
Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffoldsDan Niculescu-Duvaz, Ion Niculescu-Duvaz, Bart M J M Suijkerbuijk, et al.
Advanced Healthcare Materials|May 3, 2024
Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate CancerNiranjan Meher, Gary W Ashley, Kondapa Naidu Bobba, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2012
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A)Jonathan Seal, Yann Lamotte, Frédéric Donche, et al.
Journal of Medicinal Chemistry|December 7, 2007
4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonistsPanayiotis A Procopiou, Rachael A Ancliff, Mark J Bamford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2015
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced CancerAlex A Adjei, Donald A Richards, Anthony El-Khoueiry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2026
Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugatesAnil P Bidkar, Scott Bidlingmaier, Anju Wadhwa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2025
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac TherapyAnil P Bidkar, Robin Peter, Anju Wadhwa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2023
CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple MyelomaAnju Wadhwa, Sinan Wang, Bonell Patiño-Escobar, et al.
Pageof 33

Showing results (281-290 of 328) with videos related to

Sort By:
Pageof 33
Biorxiv : the Preprint Server for Biology|June 9, 2023
Chemoenzymatic syntheses of fluorine-18-labeled disaccharides from [ Alexandre M Sorlin, Marina López-Álvarez, Sarah J Rabbitt, et al.
Nucleic Acids Research|January 2, 2015
DNA polymerase β deficiency leads to neurodegeneration and exacerbates Alzheimer disease phenotypesPeter Sykora, Magdalena Misiak, Yue Wang, et al.
Bioorganic & Medicinal Chemistry|July 30, 2010
Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffoldsDan Niculescu-Duvaz, Ion Niculescu-Duvaz, Bart M J M Suijkerbuijk, et al.
Advanced Healthcare Materials|May 3, 2024
Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate CancerNiranjan Meher, Gary W Ashley, Kondapa Naidu Bobba, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2012
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A)Jonathan Seal, Yann Lamotte, Frédéric Donche, et al.
Journal of Medicinal Chemistry|December 7, 2007
4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonistsPanayiotis A Procopiou, Rachael A Ancliff, Mark J Bamford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2015
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced CancerAlex A Adjei, Donald A Richards, Anthony El-Khoueiry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2026
Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugatesAnil P Bidkar, Scott Bidlingmaier, Anju Wadhwa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2025
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac TherapyAnil P Bidkar, Robin Peter, Anju Wadhwa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2023
CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple MyelomaAnju Wadhwa, Sinan Wang, Bonell Patiño-Escobar, et al.
Pageof 33